It is just not emptying as fast as it used to
If Ozempic coverage is a priority and you want the freedom to see any Medicare-accepting provider in Washington (which Original Medicare + Medigap provides), the right strategy is pairing a Medigap plan with a carefully chosen Part D plan that covers your prescriptions well
The GIP receptor component provides complementary metabolic effects: Enhanced insulin sensitivity through direct action on adipose tissue Improved lipid metabolism via GIP-mediated effects on fat storage and mobilization Synergistic appetite suppression through combined incretin receptor activation in the hypothalamus Potentially better tolerated GI profile as GIP may partially offset GLP-1-mediated nausea Key Pharmacological Differences# Weight Loss Efficacy# Liraglutide (SCALE Program)# The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) was the pivotal trial for Saxenda approval: 3,731 adults without diabetes, liraglutide 3.0 mg daily for 56 weeks Mean weight loss: 8.0% (vs 2.6% placebo) 63.2% achieved 5% or more weight loss 33.1% achieved 10% or more weight loss Tirzepatide (SURMOUNT Program)# The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) established tirzepatide as a leading obesity treatment: 2,539 adults without diabetes, tirzepatide 5/10/15 mg weekly for 72 weeks Mean weight loss at 15 mg: 20.9% (vs 2.4% placebo) Mean weight loss at 10 mg: 21.4% Mean weight loss at 5 mg: 16.0% 63.2% achieved 20% or more weight loss at 15 mg Cross-Trial Comparison# While cross-trial comparisons have inherent limitations (different populations, durations, endpoints), the magnitude of difference is clear: Tirzepatide achieves approximately 2.8-fold greater mean weight loss, and the proportion reaching clinically meaningful thresholds is substantially higher across all categories
This is what we know, this is what we don't know
The fix is usually adjusting companion diabetes medications or ensuring consistent meal timing, even when appetite is minimal
